RNA 치료제 시장 : 제품 유형별, 적응증별, 최종 용도별, 세계 예측(2024-2032년)

RNA therapeutics market size is set to record 5.7% CAGR of between 2024 and 2032, driven by the increasing prevalence of chronic disorders, such as cancer, genetic disorders, and infectious diseases. As per National Institutes of Health (NIH), in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the U.S. RNA therapeutics offer the potential to address these diseases by targeting specific genes and pathways for providing more effective and personalized treatment approaches. Advancements in RNA delivery technologies, such as lipid nanoparticles and viral vectors, are enhancing the efficacy and safety profile of RNA-based drugs.

Moreover, the regulatory landscape surrounding RNA therapeutics is evolving, with regulatory agencies increasingly recognizing the potential of RNA-based drugs for streamlining the approval process. The growing adoption of personalized medicine approaches, driven by advancements in genomic sequencing and molecular diagnostics is also creating opportunities for RNA therapeutics to target specific patient populations with precision. As healthcare systems worldwide strive to improve patient outcomes and reduce healthcare costs, the demand for innovative and targeted therapies is expected to bolster the industry growth.

The RNA therapeutics market is classified on the basis of product, type, indication, end-use and region.

Based on indication, the industry size from the autoimmune disorder segment is slated to record a 6% CAGR through 2032, characterized by dysregulated immune responses targeting the body's own tissues. RNA therapeutics offer a promising avenue for treating autoimmune diseases by targeting specific molecular pathways involved in immune dysregulation. Additionally, advancements in RNA-based technologies, such as antisense oligonucleotides and small interfering RNAs, enable precise modulation of gene expression associated with autoimmune disorders, thereby offering potential therapeutic benefits.

In terms of end-use, the RNA therapeutics market from the academic & research institutes segment is anticipated to observe a 5.4% CAGR during 2024 and 2032. This is driven by advancements in the understanding of RNA biology for uncovering novel therapeutic targets and developing innovative RNA-based therapies. Moreover, academic and research institutes serve as incubators for talent and innovation for nurturing the next generation of scientists and entrepreneurs, further propelling the segment growth.

Asia Pacific RNA therapeutics industry will grow substantially at 6.1% CAGR between 2024 and 2032, attributed to the large and diverse population coupled with the high prevalence of infectious and chronic diseases. The presence of a robust biotechnology ecosystem, characterized by a network of academic research institutions, biopharmaceutical companies, and government initiatives is fostering multiple R&D activities in RNA therapeutics. Furthermore, favorable regulatory policies and increasing investments in healthcare infrastructure and biotechnology will stimulate the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculation
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of infectious diseases
    • 3.2.1.2 Advancements in RNA delivery technologies
    • 3.2.1.3 Increasing partnerships and collaborations among market players
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Recall of RNA therapeutic products
    • 3.2.2.2 High cost of development and manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vaccines
• 5.3 Drugs

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 mRNA therapeutics
• 6.3 Antisense oligonucleotide (ASO) therapeutics
• 6.4 siRNA (small interfering RNA) therapeutics
• 6.5 RNA interference (RNAi) therapeutics
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Hereditary/genetic diseases
• 7.4 Autoimmune disorders
• 7.5 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Hospitals
  • 8.1.1 Private
  • 8.1.2 Public
• 8.2 Academic & research institutes
• 8.3 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alnylam Pharmaceuticals, Inc.
• 10.2 Arrowhead Pharmaceuticals, Inc.
• 10.3 BioNTech SE
• 10.4 Ionis Pharmaceuticals
• 10.5 Moderna Inc.
• 10.6 Novartis AG
• 10.7 Orna Therapeutics, Inc.
• 10.8 Pfizer Inc.
• 10.9 Sanofi
• 10.10 Sarepta Therapeutics, Inc.